scholarly journals Self-expandable metallic stent with 125I seed strand in malignant biliary obstruction: a self-made delivery system and novel implantation method

2021 ◽  
Vol 9 (24) ◽  
pp. 1774-1774
Author(s):  
Rui An ◽  
Hu Zhang ◽  
Jing Yu ◽  
Yunbao Cao ◽  
Jialiang Ren ◽  
...  
1993 ◽  
Vol 29 (3) ◽  
pp. 457
Author(s):  
Joon Koo Han ◽  
Byung Ihn Choi ◽  
Jin Wook Chung ◽  
Jae Hyung Park ◽  
Gi Seok Han ◽  
...  

2019 ◽  
Vol 48 (4) ◽  
pp. 030006051988784
Author(s):  
Chuanguo Zhou ◽  
Hui Li ◽  
Qiang Huang ◽  
Jianfeng Wang ◽  
Kun Gao

Objective To assess the safety and effectiveness of a self-expandable metallic stent (SEMS) combined with Iodine-125 seeds strand to treat hilar malignant biliary obstruction (MBO). Methods This retrospective study included patients who had received SEMS with 125I seeds strand (seeds group) or SEMS alone (controls) to treat hilar MBO. Demographic, biochemical, stent patency, overall survival and complications data were extracted and analysed. Results A total of 76 patients were included (seeds group, n = 40; controls, n = 36), with a total of 608 seeds deployed in the seeds group (mean, 15.2 ± 4.1 [range, 8–25] seeds per patient). Statistically significant between-group differences were shown in median stent patency time (seeds group, 387.0 ± 27.9 days [95% confidence interval {CI} 332.4, 441.6] versus controls, 121.0 ± 9.1 days [95% CI 103.2, 138.8]) and in median overall survival (seeds group, 177.0 ± 17.9 days [95% CI 141.8, 212.2] versus controls, 123.0 ± 20.4 [95% CI 83.0, 163.0]). There were no statistically significant between-group differences in complication rates. Conclusion SEMS combined with 125I seeds strand is safe, feasible, and tolerable in treating patients with hilar MBO, and may be effective in prolonging stent patency time and overall survival.


2020 ◽  
Vol 93 (1108) ◽  
pp. 20190637
Author(s):  
Pyeong Hwa Kim ◽  
Jong Woo Kim ◽  
Dong Il Gwon ◽  
Gi-Young Ko ◽  
Ji Hoon Shin ◽  
...  

Objectives: To retrospectively evaluate the safety and efficacy of transcatheter arterial embolization (TAE) for delayed arterial bleeding secondary to percutaneous self-expandable metallic stent (SEMS) placement in patients with malignant biliary obstruction (MBO). Methods: From January 1997 to September 2017, 1858 patients underwent percutaneous SEMS placement for MBO at a single tertiary referral center. Among them, 19 patients (mean age, 70.2 [range, 52–82] years; 13 men) presented with delayed SEMS-associated arterial bleeding and underwent TAE. Results: The incidence of delayed arterial bleeding was 1.0% (19/1858) after SEMS placement, with a median time interval of 225 days (range, 22–2296). Digital subtraction angiography (DSA) showed pseudoaneurysm alone close to the stent mesh (n = 10), pseudoaneurysm close to the stent mesh with contrast extravasation to the duodenum (n = 3), pseudoaneurysm close to the stent mesh with arteriobiliary fistula (n = 1), in-stent pseudoaneurysm alone (n = 4) and in-stent pseudoaneurysm with arteriobiliary fistula (n = 1). Bleeding was stopped after the embolization in all patients. Overall clinical success rate was 94.7% (18/19). One patient with recurrent bleeding was successfully treated with a second embolization. Overall 30-day mortality rate was 26.3% (5/19). A major procedure-related complication was acute hepatic failure in one hilar bile duct cancer patient (5.3%), which was associated with an obliterated portal vein. Conclusion: TAE is safe and effective for the treatment of delayed arterial bleeding after percutaneous SEMS placement for MBO. Advances in knowledge: This study demonstrated TAE is safe and effective for arterial bleeding after SEMS placement after MBO through the largest case series so far.


Sign in / Sign up

Export Citation Format

Share Document